^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20 inhibitor

    Related drugs:
    1d
    Neuro-related gene signatures predict prognosis in diffuse large B-Cell lymphoma and uncover TRPV2-mediated tumor microenvironment regulation. (PubMed, Ann Hematol)
    Although the R-CHOP regimen has significantly improved the prognosis for most patients, a subset continues to experience poor therapeutic outcomes...The key gene TRPV2, associated with favorable prognosis, was found to promote M1-like polarization in monocytes/macrophages and enhance antigen presentation in B cells. This study establishes the NR risk score as a novel prognostic tool for DLBCL and underscores neuro-immune interactions as potential therapeutic targets.
    Journal • Gene Signature
    |
    TP53 (Tumor protein P53) • TRPV2 (Transient Receptor Potential Cation Channel Subfamily V Member 2)
    |
    TP53 mutation
    |
    Rituxan (rituximab)
    3d
    A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=80, Enrolling by invitation, Second Affiliated Hospital of Nanchang University
    New P3 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • decitabine
    4d
    Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel. (PubMed, Blood Adv)
    Kaplan-Meier analysis of R-CHOP-treated patients with DLBCL-NOS revealed that those with MCD, BN2, and A53 subtypes had poorer overall survival than those with EZB and ST2, particularly among patients with concurrent MYC/BCL2 DE. Using a clinically applicable NGS panel, we successfully implemented the LymphGen classification system. This study underscores the distinct genetic landscape of Korean DLBCL and highlights the utility of LymphGen in identifying high-risk subgroups, providing a basis for prognostic stratification and therapeutic optimization.
    Journal • Next-generation sequencing • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    MSK-IMPACT
    |
    Rituxan (rituximab)
    4d
    RITZ: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients (clinicaltrials.gov)
    P3, N=122, Active, not recruiting, International Extranodal Lymphoma Study Group (IELSG) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • MME (Membrane Metalloendopeptidase) • ITGAE (Integrin Subunit Alpha E)
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)
    5d
    Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna
    5d
    EPCORE DLBCL-3: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=111, Active, not recruiting, Genmab | Trial completion date: Jul 2027 --> Jun 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    lenalidomide • Epkinly (epcoritamab-bysp)
    5d
    Glofitamab in Real Life (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting | Trial completion date: Nov 2026 --> Jul 2026 | Initiation date: Aug 2025 --> Dec 2025 | Trial primary completion date: Nov 2025 --> Mar 2026
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    Columvi (glofitamab-gxbm)
    10d
    EPCORE NHL-2: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (clinicaltrials.gov)
    P1/2, N=543, Active, not recruiting, Genmab | Trial completion date: Sep 2028 --> Sep 2027 | Trial primary completion date: Sep 2028 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    carboplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • prednisone • dexamethasone • bendamustine • Epkinly (epcoritamab-bysp)
    11d
    Glofitamab Combined With CAR-T Therapy in R/R DLBCL (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Gazyva (obinutuzumab) • Yescarta (axicabtagene ciloleucel) • Carteyva (relmacabtagene autoleucel) • Columvi (glofitamab-gxbm)
    11d
    Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis (clinicaltrials.gov)
    P1, N=90, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ordspono (odronextamab) • vonsetamig (REGN5459)
    12d
    EPCORE CLL-1: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (clinicaltrials.gov)
    P1/2, N=424, Recruiting, Genmab | Trial completion date: Aug 2029 --> Apr 2028 | Trial primary completion date: Jun 2029 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)
    12d
    STARGLO: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=270, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Feb 2026 --> Mar 2028 | Trial primary completion date: Feb 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    gemcitabine • Rituxan (rituximab) • Gazyva (obinutuzumab) • oxaliplatin • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)